| # | Drug | Count |
|---|---|---|
| 0 | DINUTUXIMAB | 89 |
| 1 | CYCLOPHOSPHAMIDE | 68 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 68 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 68 |
| 4 | ETOPOSIDE | 58 |
| 5 | FILGRASTIM | 53 |
| 6 | ACETAMINOPHEN | 42 |
| 7 | ACETAMINOPHEN 500MG | 42 |
| 8 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 42 |
| 9 | PAIN RELIEVER | 42 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DINUTUXIMAB | 89 | 0.1036 |
| 1 | IOBENGUANE I-123 | 5 | 0.0439 |
| 2 | NAXITAMAB | 8 | 0.0320 |
| 3 | EFLORNITHINE HYDROCHLORIDE | 1 | 0.0238 |
| 4 | TOPOTECAN | 27 | 0.0044 |
| 5 | SARGRAMOSTIM | 7 | 0.0040 |
| 6 | TOPOTECAN HYDROCHLORIDE | 6 | 0.0025 |
| 7 | LORLATINIB | 18 | 0.0024 |
| 8 | ALDESLEUKIN | 3 | 0.0024 |
| 9 | DEXRAZOXANE FOR INJECTION | 2 | 0.0021 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 97 |
| 1 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 89 |
| 2 | Leukocyte Growth Factor [EPC] | 81 |
| 3 | Topoisomerase Inhibitor [EPC] | 68 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 43 |
| 5 | Platinum-based Drug [EPC] | 35 |
| 6 | Benzodiazepine [EPC] | 20 |
| 7 | Histamine-2 Receptor Antagonist [EPC] | 20 |
| 8 | Kinase Inhibitor [EPC] | 20 |
| 9 | Retinoid [EPC] | 19 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 89 | 0.0820 |
| 1 | Lymphocyte Growth Factor [EPC] | 3 | 0.0024 |
| 2 | Histone Deacetylase Inhibitor [EPC] | 4 | 0.0010 |
| 3 | Topoisomerase Inhibitor [EPC] | 68 | 0.0009 |
| 4 | Leukocyte Growth Factor [EPC] | 81 | 0.0006 |
| 5 | Actinomycin [EPC] | 1 | 0.0005 |
| 6 | Alkylating Drug [EPC] | 97 | 0.0004 |
| 7 | Histamine-2 Receptor Antagonist [EPC] | 20 | 0.0002 |
| 8 | Thrombopoietin Receptor Agonist [EPC] | 2 | 0.0001 |
| 9 | Platinum-based Drug [EPC] | 35 | 0.0001 |